The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.25 (9.091%)
Open: 2.875
High: 2.95
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

Fri, 20th Nov 2020 14:51

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

----------

Land Securities Group PLC - London-based commercial property developer - Chief Executive Officer Mark Allan buys 45,695 shares at GBP6.82, worth GBP311,772, on Thursday. Landsec last week reported a wider interim loss and a fall in net asset value but reinstated its dividend.

----------

SSE PLC - electricity utility based in Perth, Scotland - Colin Nicol, outgoing managing director of electricity distribution business, SSEN Distribution, sells 18,212 shares at GBP14.11, worth GBP256,990, on Wednesday.

----------

RSA Insurance Group PLC - London-based general insurance - Chief Legal Officer Charlotte Heiss sells 29,968 shares at GBP6.75, worth GBP202,344, on Thursday. RSA on Wednesday said it has reached an agreement to be sold and split up in a deal with a two-headed consortium which values the former Royal & Sun Alliance Insurance Group at GBP7.2 billion.

----------

Spirent Communications PLC - Crawley, England-based provider of testing, analytics and security for telecommunications networks - Dean Ritchie, associate of Chief Financial Officer Paula Bell, buys 50,000 shares at GBP2.57, worth GBP128,740, on Thursday. Bell now interested in 363,884 shares.

----------

Jardine Matheson Holdings Ltd - Hong Kong-headquartered holding company with interests in retail, property, hotels and motor dealerships - Ruby Weatherall, associate of Director Percy Weatherall, sells 3,100 shares at USD51.35, worth USD159,193, in Singapore on Thursday.

----------

H&T Group PLC - Surrey, England-based pawnbroker - CFO Richard Withers buys 10,000 shares for 227.4 pence, worth GBP22,740, on Wednesday.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Non-Executive Chair Peter Jensen buys 100,000 shares at 14p, worth GBP14,000, on Thursday.

----------

easyJet PLC - Luton Airport-based budget airline - Non-Executive Director Nicholas Leeder buys 1,346 shares mostly at GBP7.53, worth GBP10,140, on Thursday.

----------

Henderson High Income Trust PLC - investment trust aiming for high-income stream and prospects of capital growth - Director Jeremy Rigg buys 10,000 shares at GBP1.46, worth GBP14,605, on Friday.

----------

Dunedin Enterprise Investment Trust PLC - invests in UK mid-market companies - Directors sell shares as part of company's tender offer at GBP3.85 on November 12. Brian and Fionnlagh Finlayson sell 27,572 shares. Duncan, Rosemary and Victoria Budge sell 12,449 shares. Angela and David Lane sell 4,307. Company bought back 2.5 million shares in total, spending about GBP9.8 million.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
26 Oct 2020 13:37

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

Read more
23 Sep 2020 14:02

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

Read more
4 Sep 2020 19:39

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Read more
3 Sep 2020 15:31

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
15 Jul 2020 09:03

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.

Read more
9 Jul 2020 21:19

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Read more
9 Jul 2020 16:26

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.

Read more
24 Jun 2020 11:53

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Read more
24 Jun 2020 10:12

Allergy Therapeutics on track to 'significantly' exceed FY expectations

(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.

Read more
4 Mar 2020 10:46

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Read more
26 Feb 2020 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
16 Jan 2020 13:28

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Read more
26 Nov 2019 14:15

Allergy Therapeutics to take 'stepwise approach' to upcoming grass study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.

Read more
25 Sep 2019 11:26

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.